Processa Pharmaceuticals (NASDAQ:PCSA) received a reiterated Buy rating and a $6.00 price target from H.C. Wainwright. This affirmation follows Processa Pharmaceuticals' announcement on Monday of positive data from preclinical studies.
The studies suggest that NGC-Iri, the company's proprietary irinotecan-based construct, could potentially show enhanced clinical efficacy and safety compared to the FDA-approved chemotherapeutic agents native irinotecan and Onivyde.
The analyst from H.C. Wainwright highlighted the significance of the recent preclinical study results for Processa Pharmaceuticals. According to the analyst, the data support the potential for NGC-Iri to exhibit improved outcomes over the existing treatments. Native irinotecan, known by the trade name Camptosar, and Onivyde, a liposomal formulation of irinotecan approved by the FDA in October 2015, are the current standards in chemotherapy treatments that NGC-Iri aims to outperform.
Processa Pharmaceuticals aims to advance NGC-Iri as a more effective and safer alternative to these established chemotherapeutic agents. The preclinical study results are a crucial step in the development process, providing early indications of NGC-Iri's comparative advantages.
The analyst's maintained Buy rating and price target reflect a positive outlook for Processa Pharmaceuticals' stock over a 12-month period. The $6.00 price target is based on the prospects of NGC-Iri as it progresses through the development pipeline.
The preclinical data serves as a foundation for the company's continued research and development activities.
Processa Pharmaceuticals' announcement and the subsequent analyst endorsement underscore the company's progress in developing NGC-Iri. As the company moves forward with its clinical programs, investors and stakeholders will be watching closely for further developments that could impact the stock's performance and the potential benefits to patients undergoing chemotherapy.
The company reported promising results from preclinical studies of its new drug candidate NGC-Iri, which demonstrated a higher concentration of the cancer-fighting molecule SN-38 in tumors. H.C. Wainwright revised its 12-month price target for Processa to $6, maintaining a Buy rating despite the company's recent Q2 financial results revealing a net loss of $1.01 per share.
The U.S. Food and Drug Administration (FDA) has also cleared Processa's Investigational New Drug (IND) application for a Phase 2 clinical trial of its lead product candidate, Next Generation Capecitabine (NGC-Cap), in patients with advanced or metastatic breast cancer.
Russell L. Skibsted has been appointed as the new Chief Financial Officer, succeeding the retiring James Stanker. In a recent meeting, Processa's shareholders approved key proposals, including the election of six directors and the amendment and restatement of the company's 2019 Omnibus Incentive Plan.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.